Henlius share prices surges as buyout offer values the company at $1.71 billion

World’s most widely used mRNA vaccine languishes unapproved in China as Fosun Pharma and BioNTech see window of opportunity closing

Closely held Genuine Biotech aims to generate funds to make and commercialize Azvudine and to develop other drugs

German developer’s mRNA-based Comirnaty shot is one of the most widely used worldwide, with data already showing its high efficacy

Company still waiting for approval to manufacture and sell German-developed Covid vaccine to Chinese mainland

Drug regulators complete an expert review of a Covid-19 mRNA jab developed by Fosun Pharma and the German pharmaceutical company

China pledges to provide more support for foreign trade even as exports surge. Suning.com founder steps down as chairman after state bailout. Fosun seals a deal to sell mRNA vaccines to Taiwan. A polysilicon manufacturer under U.S. sanctions will list in Shanghai.

Shanghai-based drug giant will sell 10 million doses of BioNTech’s cutting-edge Covid-19 vaccine to groups connected to local billionaire Terry Gou, chipmaker TSMC

Advanced mRNA vaccine for Covid-19 nears completion of regulatory reviews as drugmakers start preparing Shanghai factory

Pair will build Shanghai factory with capacity to make 1 billion doses of German company’s mRNA-based inoculations each year

German pharmaceutical giant is ‘very encouraged’ by safety and efficacy of coronavirus inoculation it co-developed with Pfizer, company CEO says

Deal with domestic player Fosun for ‘initial supply’ leaves door open to local production in future

Gland Pharma, billionaire Guo Guangchang’s Fosun and other holders plan to sell $871 million of Gland shares and list in Mumbai

Chinese company had previously been pushing to produce BioNTech’s vaccine locally

Shanghai drugmaker would supply 10 million doses of partner BioNTech’s RNA-based Covid-19 inoculations under deal that eventually extends to mainland

Firm sees strong increase in revenue, up 26.7% to 18.5 billion yuan

Purchase of 74% rather than original 86% of Gland Pharma would guarantee New Delhi’s regulatory approval